Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre-Xabier, Nita Patel, Jing-Hui Tian, Bin Zhou, Sonia Maciejewski, Kristal Lam, Alyse D. Portnoff, Michael J. Massare, Matthew B. Frieman, Pedro A. Piedra, Larry Ellingsworth, Gregory Glenn, Gale Smith
doi: https://doi.org/10.1101/2020.08.18.256578
Mimi Guebre-Xabier
1Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. (M.G.X.), (N.P.), (J.H.T.), (B.Z.), (S.M.), (K.L.), (A.D.P.), (M.J.M.), (L.E.), (G.G.), (G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mguebre-xabier@Novavax.com npatel@novavax.com jhtian@Novavax.com bzhou@Novavax.com smaciejewski@Novavavax.com klam@Novavax.com aportnoff@Novavax.com mmassare@Novavax.com lellingsworth@novavax.com gglenn@Novavax.com gsmith@Novavax.com
Nita Patel
1Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. (M.G.X.), (N.P.), (J.H.T.), (B.Z.), (S.M.), (K.L.), (A.D.P.), (M.J.M.), (L.E.), (G.G.), (G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mguebre-xabier@Novavax.com npatel@novavax.com jhtian@Novavax.com bzhou@Novavax.com smaciejewski@Novavavax.com klam@Novavax.com aportnoff@Novavax.com mmassare@Novavax.com lellingsworth@novavax.com gglenn@Novavax.com gsmith@Novavax.com
Jing-Hui Tian
1Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. (M.G.X.), (N.P.), (J.H.T.), (B.Z.), (S.M.), (K.L.), (A.D.P.), (M.J.M.), (L.E.), (G.G.), (G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mguebre-xabier@Novavax.com npatel@novavax.com jhtian@Novavax.com bzhou@Novavax.com smaciejewski@Novavavax.com klam@Novavax.com aportnoff@Novavax.com mmassare@Novavax.com lellingsworth@novavax.com gglenn@Novavax.com gsmith@Novavax.com
Bin Zhou
1Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. (M.G.X.), (N.P.), (J.H.T.), (B.Z.), (S.M.), (K.L.), (A.D.P.), (M.J.M.), (L.E.), (G.G.), (G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mguebre-xabier@Novavax.com npatel@novavax.com jhtian@Novavax.com bzhou@Novavax.com smaciejewski@Novavavax.com klam@Novavax.com aportnoff@Novavax.com mmassare@Novavax.com lellingsworth@novavax.com gglenn@Novavax.com gsmith@Novavax.com
Sonia Maciejewski
1Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. (M.G.X.), (N.P.), (J.H.T.), (B.Z.), (S.M.), (K.L.), (A.D.P.), (M.J.M.), (L.E.), (G.G.), (G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mguebre-xabier@Novavax.com npatel@novavax.com jhtian@Novavax.com bzhou@Novavax.com smaciejewski@Novavavax.com klam@Novavax.com aportnoff@Novavax.com mmassare@Novavax.com lellingsworth@novavax.com gglenn@Novavax.com gsmith@Novavax.com
Kristal Lam
1Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. (M.G.X.), (N.P.), (J.H.T.), (B.Z.), (S.M.), (K.L.), (A.D.P.), (M.J.M.), (L.E.), (G.G.), (G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mguebre-xabier@Novavax.com npatel@novavax.com jhtian@Novavax.com bzhou@Novavax.com smaciejewski@Novavavax.com klam@Novavax.com aportnoff@Novavax.com mmassare@Novavax.com lellingsworth@novavax.com gglenn@Novavax.com gsmith@Novavax.com
Alyse D. Portnoff
1Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. (M.G.X.), (N.P.), (J.H.T.), (B.Z.), (S.M.), (K.L.), (A.D.P.), (M.J.M.), (L.E.), (G.G.), (G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mguebre-xabier@Novavax.com npatel@novavax.com jhtian@Novavax.com bzhou@Novavax.com smaciejewski@Novavavax.com klam@Novavax.com aportnoff@Novavax.com mmassare@Novavax.com lellingsworth@novavax.com gglenn@Novavax.com gsmith@Novavax.com
Michael J. Massare
1Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. (M.G.X.), (N.P.), (J.H.T.), (B.Z.), (S.M.), (K.L.), (A.D.P.), (M.J.M.), (L.E.), (G.G.), (G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mguebre-xabier@Novavax.com npatel@novavax.com jhtian@Novavax.com bzhou@Novavax.com smaciejewski@Novavavax.com klam@Novavax.com aportnoff@Novavax.com mmassare@Novavax.com lellingsworth@novavax.com gglenn@Novavax.com gsmith@Novavax.com
Matthew B. Frieman
2University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA. (M.B.F.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mfrieman@som.umaryland.edu
Pedro A. Piedra
3Department of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine, Houston, Texas. (P.A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ppiedra@bcm.edu
Larry Ellingsworth
1Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. (M.G.X.), (N.P.), (J.H.T.), (B.Z.), (S.M.), (K.L.), (A.D.P.), (M.J.M.), (L.E.), (G.G.), (G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mguebre-xabier@Novavax.com npatel@novavax.com jhtian@Novavax.com bzhou@Novavax.com smaciejewski@Novavavax.com klam@Novavax.com aportnoff@Novavax.com mmassare@Novavax.com lellingsworth@novavax.com gglenn@Novavax.com gsmith@Novavax.com
Gregory Glenn
1Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. (M.G.X.), (N.P.), (J.H.T.), (B.Z.), (S.M.), (K.L.), (A.D.P.), (M.J.M.), (L.E.), (G.G.), (G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mguebre-xabier@Novavax.com npatel@novavax.com jhtian@Novavax.com bzhou@Novavax.com smaciejewski@Novavavax.com klam@Novavax.com aportnoff@Novavax.com mmassare@Novavax.com lellingsworth@novavax.com gglenn@Novavax.com gsmith@Novavax.com
Gale Smith
1Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. (M.G.X.), (N.P.), (J.H.T.), (B.Z.), (S.M.), (K.L.), (A.D.P.), (M.J.M.), (L.E.), (G.G.), (G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gsmith@Novavax.com mguebre-xabier@Novavax.com npatel@novavax.com jhtian@Novavax.com bzhou@Novavax.com smaciejewski@Novavavax.com klam@Novavax.com aportnoff@Novavax.com mmassare@Novavax.com lellingsworth@novavax.com gglenn@Novavax.com gsmith@Novavax.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

ABSTRACT

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective efficacy of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) produced from the full-length SARS-CoV-2 spike (S) glycoprotein stabilized in the prefusion conformation. Cynomolgus macaques (Macaca fascicularis) immunized with NVX-CoV2373 and the saponin-based Matrix-M adjuvant induced anti-S antibody that was neutralizing and blocked binding to the human angiotensin-converting enzyme 2 (hACE2) receptor. Following intranasal and intratracheal challenge with SARS-CoV-2, immunized macaques were protected against upper and lower infection and pulmonary disease. These results support ongoing phase 1/2 clinical studies of the safety and immunogenicity of NVX-CoV2327 vaccine (NCT04368988).

Highlights

  • Full-length SARS-CoV-2 prefusion spike with Matrix-M1™ (NVX-CoV2373) vaccine.

  • Induced hACE2 receptor blocking and neutralizing antibodies in macaques.

  • Vaccine protected against SARS-CoV-2 replication in the nose and lungs.

  • Absence of pulmonary pathology in NVX-CoV2373 vaccinated macaques.

Competing Interest Statement

Authors MGX, NP, JHT, BZ, SM, KL, ADP, MJM, GG, GS and LE are current or past employees of Novavax Inc. a for-profit organization and these authors own stock or hold stock options. These interests do not alter the authors adherence to policies on sharing data and materials. MBF and PAP declare no competing interests.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 19, 2020.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
Mimi Guebre-Xabier, Nita Patel, Jing-Hui Tian, Bin Zhou, Sonia Maciejewski, Kristal Lam, Alyse D. Portnoff, Michael J. Massare, Matthew B. Frieman, Pedro A. Piedra, Larry Ellingsworth, Gregory Glenn, Gale Smith
bioRxiv 2020.08.18.256578; doi: https://doi.org/10.1101/2020.08.18.256578
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
Mimi Guebre-Xabier, Nita Patel, Jing-Hui Tian, Bin Zhou, Sonia Maciejewski, Kristal Lam, Alyse D. Portnoff, Michael J. Massare, Matthew B. Frieman, Pedro A. Piedra, Larry Ellingsworth, Gregory Glenn, Gale Smith
bioRxiv 2020.08.18.256578; doi: https://doi.org/10.1101/2020.08.18.256578

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Immunology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4384)
  • Biochemistry (9610)
  • Bioengineering (7104)
  • Bioinformatics (24898)
  • Biophysics (12632)
  • Cancer Biology (9974)
  • Cell Biology (14374)
  • Clinical Trials (138)
  • Developmental Biology (7966)
  • Ecology (12126)
  • Epidemiology (2067)
  • Evolutionary Biology (16003)
  • Genetics (10936)
  • Genomics (14756)
  • Immunology (9881)
  • Microbiology (23700)
  • Molecular Biology (9490)
  • Neuroscience (50926)
  • Paleontology (370)
  • Pathology (1541)
  • Pharmacology and Toxicology (2687)
  • Physiology (4023)
  • Plant Biology (8674)
  • Scientific Communication and Education (1512)
  • Synthetic Biology (2402)
  • Systems Biology (6444)
  • Zoology (1346)